Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Avai Bio (AVAI) EBIT (2018 - 2024)

Avai Bio's EBIT history spans 6 years, with the latest figure at -$4.8 million for Q1 2024.

  • For Q1 2024, EBIT fell 738.05% year-over-year to -$4.8 million; the TTM value through Mar 2024 reached -$3.0 million, down 753.0%, while the annual FY2025 figure was -$1.1 million, 61.63% up from the prior year.
  • EBIT for Q1 2024 was -$4.8 million at Avai Bio, down from $1.0 million in the prior quarter.
  • Across five years, EBIT topped out at $1.0 million in Q4 2023 and bottomed at -$4.8 million in Q1 2024.
  • The 4-year median for EBIT is $78324.0 (2020), against an average of -$273817.9.
  • The largest YoY upside for EBIT was 4203.92% in 2020 against a maximum downside of 1770.01% in 2020.
  • A 4-year view of EBIT shows it stood at $417163.0 in 2020, then plummeted by 73.52% to $110471.0 in 2022, then skyrocketed by 817.8% to $1.0 million in 2023, then plummeted by 573.56% to -$4.8 million in 2024.
  • Per Business Quant, the three most recent readings for AVAI's EBIT are -$4.8 million (Q1 2024), $1.0 million (Q4 2023), and $399621.0 (Q3 2023).